Medical Oncologist
Targeted therapy eligibility
Who Is Eligible for — Osimertinib (Tagrisso)?
Osimertinib works only when your tumour carries a specific EGFR mutation. The first step is not choosing a treatment — it is finding out whether your molecular test result makes it an option for you.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- A specific mutation decides it — Osimertinib is not for all lung cancer — only for tumours that carry certain EGFR mutations.
- Testing comes before treatment — Molecular testing of your tumour tissue or blood establishes whether osimertinib is appropriate.
- More common in never-smokers — EGFR mutations are found more often in people who have never smoked, and in South and East Asian populations.
- Used at more than one stage — Osimertinib may be given as an initial treatment, after surgery, or when an earlier EGFR drug has stopped working.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Osimertinib (Tagrisso) is for non-small cell lung cancer that carries an EGFR exon 19 deletion, an exon 21 L858R mutation, or a T790M resistance mutation. Your oncologist establishes eligibility from molecular testing of your tumour tissue or a blood sample. Without a confirmed EGFR mutation of the right type, osimertinib is not indicated.
Which patients are eligible for osimertinib and which are not?
| Factor | Eligible | Not eligible |
|---|---|---|
| Mutation present | EGFR exon 19 deletion, exon 21 L858R, or T790M confirmed on testing | No EGFR mutation found, or a different driver mutation such as KRAS or ALK rearrangement |
| Cancer type | Non-small cell lung cancer (NSCLC) | Small cell lung cancer |
| Setting | Metastatic disease (stage IV), or early stage after complete surgical resection with confirmed mutation | Not established as standard across all intermediate stages — your oncologist will advise |
| Prior EGFR treatment | No prior EGFR drug (for first-line use), or progressed on earlier EGFR drug with T790M now confirmed | Progressed on earlier EGFR drug without T790M mutation on repeat testing |
| Organ function | Adequate heart, liver, and lung function as assessed by your team | Significant QTc prolongation on ECG or severe organ impairment may exclude you |
What does your team need to confirm before osimertinib can be considered?
- A confirmed diagnosis of non-small cell lung cancer, from a biopsy
- Molecular testing of the tumour tissue or a blood sample (liquid biopsy)
- A result showing EGFR exon 19 deletion, L858R, or T790M mutation specifically
- Staging scans to establish how far the cancer has spread
- An ECG to assess heart rhythm, as osimertinib can affect the QTc interval
- A review of other medicines you take, as some interact with osimertinib
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do the terms on your test report actually mean?
- EGFR
- Epidermal growth factor receptor — a protein on the surface of cells. When the gene that makes this protein carries a mutation, it can drive cancer growth. Osimertinib blocks the mutated version.
- Exon 19 deletion
- A section of the EGFR gene where a small piece of DNA is missing. This is one of the two most common EGFR mutations in lung cancer, and it is a qualifying mutation for osimertinib.
- L858R mutation
- A change in the EGFR gene at a specific position, where one building block of the protein is swapped for another. This is the other most common qualifying EGFR mutation, and osimertinib targets it directly.
- T790M mutation
- A change that often develops in the EGFR gene after a first- or second-generation EGFR drug has been used for some time, causing resistance. Osimertinib was specifically designed to overcome this resistance.
- Liquid biopsy
- A blood test that looks for tumour DNA circulating in the bloodstream. It can identify EGFR mutations without a new tissue biopsy, though tissue biopsy remains the reference standard where it is possible.
Why does the mutation type matter so much?
Osimertinib blocks a specific, mutated form of the EGFR protein. It does not act against the normal version, and it does not work against lung cancers driven by a completely different gene.
This is why two people with lung cancer at the same stage can be offered entirely different treatments. The stage tells you how far the cancer has spread. The mutation tells you which treatment the cancer is most likely to respond to.
If your test came back without a qualifying EGFR mutation, being told osimertinib is not for you is information about which treatment fits your cancer's biology — it is not a statement about your outlook or how treatable your cancer is.
Did you know?
EGFR mutations are detected in a meaningfully higher proportion of Indian patients with non-squamous NSCLC than in most European patient groups — a difference linked to both genetic background and the larger share of never-smokers among Indian NSCLC patients.
This makes molecular testing particularly important in India: a greater proportion of patients who test positive will carry a mutation that a drug like osimertinib can specifically target.
Source: Indian Council of Medical Research (ICMR); ESMO Asia guidelines on NSCLC
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
My report says EGFR mutation detected. Does that mean I can take osimertinib?
Not automatically, because the report needs to tell you which EGFR mutation was found, not just that one is present. Exon 19 deletion and L858R are the two qualifying mutations for first-line osimertinib. Some less common EGFR mutations — such as exon 20 insertions — are generally not targeted by osimertinib, and different drugs are used for those. Ask your oncologist to show you the exact mutation name from the report, not just whether EGFR was positive or negative.
I smoke. Can I still be eligible for osimertinib?
Yes. EGFR mutations are more common in people who have never smoked, but they do occur in people who smoke or who smoked in the past. Your smoking history does not determine eligibility — your molecular test result does. If you have NSCLC and have not had molecular testing, ask your oncologist about it regardless of your smoking history.
I was already on gefitinib or erlotinib and it stopped working. Can I switch to osimertinib?
Possibly, but a repeat molecular test is needed first. When first- or second-generation EGFR drugs stop working, the most common cause is the development of a T790M resistance mutation. Osimertinib was designed specifically to overcome T790M, and NCCN and ESMO guidance supports it as the next step when T790M is confirmed. If the resistance mechanism turns out to be something other than T790M, osimertinib is unlikely to help, and your oncologist will explain what other options apply.
I have had surgery to remove a lung tumour. Does eligibility for osimertinib still apply?
It can. Osimertinib may also be recommended after surgery in early-stage NSCLC to reduce the risk of the cancer returning. If you had a complete resection with an EGFR exon 19 deletion or L858R mutation confirmed, adjuvant osimertinib may be part of your follow-up plan according to NCCN and ESMO guidance. This is a separate decision from the metastatic setting, so ask your surgeon and oncologist together whether adjuvant treatment applies to your situation.
Is molecular testing available outside the main cities in India?
Access has improved significantly. Accredited molecular pathology laboratories now operate across most major cities, and tumour tissue samples can be sent to them from centres that do not have on-site testing. ICMR guidance supports making EGFR testing standard practice for all newly diagnosed NSCLC patients. If you have been told testing is unavailable where you are being treated, ask whether your tissue block can be sent to a specialist laboratory — this is a routine step in most large centres.
What happens if I am not eligible for osimertinib?
Being ineligible means a different treatment fits your cancer's biology better. Depending on what your full molecular results show, your oncologist may recommend a different targeted therapy — for example, an ALK inhibitor if you carry an ALK rearrangement — or chemotherapy, immunotherapy, or a combination of these. Incomplete testing leads to the wrong treatment choice, so if you are not sure that full molecular testing was done, it is reasonable to ask before a treatment plan is finalised.